🇺🇸 FDA
Patent

US 10435428

Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease

granted A61PA61P1/00A61P1/04

Quick answer

US patent 10435428 (Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease) held by Theravance Biopharma R&D IP, LLC expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P1/00, A61P1/04, A61P29/00